Charles River to close ‘15 smaller sites’ as demand for early research declinesnews2024-11-08T16:28:38+00:00November 8th, 2024|Endpoints News|
Nkarta drops another cancer program as it leans into autoimmune diseasenews2024-11-08T11:59:06+00:00November 8th, 2024|Endpoints News|
Athira gives up on lead Alzheimer’s drug, switches tack to ALSnews2024-11-08T11:54:06+00:00November 8th, 2024|Endpoints News|
Genmab chops early cancer prospects to prioritize Phase 3 projectsnews2024-11-07T16:21:56+00:00November 7th, 2024|Endpoints News|
Aurinia cuts nearly half of its workforce in second round of layoffs this yearnews2024-11-07T16:18:12+00:00November 7th, 2024|Endpoints News|
Denali teases early data for enzyme replacement therapy in rare diseasenews2024-11-07T14:49:55+00:00November 7th, 2024|Endpoints News|
Gilead beats Covid drug sales forecasts, takes $1.75B hit on Trodelvy study failnews2024-11-07T12:27:53+00:00November 7th, 2024|Endpoints News|
Arcus backs TIGIT combo by offering glimpse at positive data from axed trialnews2024-11-07T12:06:55+00:00November 7th, 2024|Endpoints News|
Sarepta discontinues work on next-gen exon-skipping drug for Duchennenews2024-11-07T10:39:11+00:00November 7th, 2024|Endpoints News|
At this year’s ObesityWeek, GLP-1s aren’t the only talk of the townnews2024-11-06T14:23:27+00:00November 6th, 2024|Endpoints News|
